GT Biopharma, Inc. (GTBP) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
505 MONTGOMERY STREET SAN FRANCISCO, CA 94111 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2025 MRQ | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 3,951 | 14,000 | 16,508 | 32,000 | 5,297 | 28 | |||
| Cash and cash equivalent | 3,951 | 1,079 | 5,672 | 9,218 | 5,297 | 28 | |||
| Short-term investments | 12,893 | 10,836 | 23,011 | ||||||
| Other undisclosed cash, cash equivalents, and short-term investments | 28 | (229) | |||||||
| Restricted cash and investments | 93 | ||||||||
| Prepaid expense | 190 | 364 | 246 | ||||||
| Deferred costs | |||||||||
| Other undisclosed current assets | 188 | 56 | 54 | (21) | |||||
| Total current assets: | 4,232 | 14,056 | 16,562 | 32,169 | 5,661 | 274 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 53 | 165 | |||||||
| Deposits noncurrent assets | 9 | 12 | |||||||
| Other undisclosed noncurrent assets | 110 | ||||||||
| Total noncurrent assets: | 53 | 174 | 122 | ||||||
| TOTAL ASSETS: | 4,232 | 14,109 | 16,736 | 32,169 | 5,661 | 396 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 5,650 | 5,523 | 4,809 | 10,090 | 8,377 | 6,348 | |||
| Interest and dividends payable | ✕ | ✕ | ✕ | ✕ | 4,838 | 2,029 | |||
| Accounts payable | 3,853 | 4,328 | 3,140 | 8,189 | 2,243 | 1,940 | |||
| Accrued liabilities | 1,797 | 1,195 | 1,669 | 1,901 | 1,296 | 2,379 | |||
| Debt | 31 | 26,303 | 13,207 | ||||||
| Derivative instruments and hedges, liabilities | 19 | 138 | 383 | ||||||
| Other undisclosed current liabilities | 252 | 1,110 | 110 | 31 | 151 | ||||
| Total current liabilities: | 5,902 | 6,633 | 4,938 | 10,259 | 35,094 | 19,706 | |||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 64 | ||||||||
| Operating lease, liability | 64 | ||||||||
| Total noncurrent liabilities: | 64 | ||||||||
| Total liabilities: | 5,902 | 6,633 | 5,002 | 10,259 | 35,094 | 19,706 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (1,670) | 7,476 | 11,734 | 21,910 | (29,433) | (19,310) | |||
| Preferred stock | 1 | 1 | 1 | 3 | |||||
| Common stock | 2 | 1 | 33 | 32 | 52 | 70 | |||
| Additional paid in capital | 693,554 | 689,539 | 686,168 | 674,348 | 566,309 | 548,118 | |||
| Accumulated deficit | (695,227) | (682,065) | (674,468) | (653,584) | (595,628) | (567,332) | |||
| Other undisclosed equity, attributable to parent | 1,114 | (169) | (166) | ||||||
| Total equity: | (1,670) | 7,476 | 11,734 | 21,910 | (29,433) | (19,310) | |||
| Other undisclosed liabilities and equity | |||||||||
| TOTAL LIABILITIES AND EQUITY: | 4,232 | 14,109 | 16,736 | 32,169 | 5,661 | 396 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues (gain on Disposition of Assets for Financial Service Operations) | 31,979 | |||||||
| Gross profit: | 31,979 | |||||||
| Operating expenses | (14,364) | (13,576) | (21,257) | (57,515) | (6,764) | (16,056) | ||
| Other undisclosed operating income (loss) | (31,979) | 13,528 | ||||||
| Operating income (loss): | (14,364) | (13,576) | (21,257) | (57,515) | 6,764 | (16,056) | ||
| Nonoperating income (expense) | 1,202 | 5,979 | 373 | (498) | 21,532 | (22,591) | ||
| Investment income, nonoperating | 12,598 | (4,599) | ||||||
| Interest and debt expense | (213) | 31 | 3,003 | (2,128) | ||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (13,162) | (7,810) | (20,853) | (58,013) | 31,299 | (40,775) | ||
| Other undisclosed income from continuing operations before income taxes | 2,128 | |||||||
| Income (loss) from continuing operations: | (13,162) | (7,810) | (20,853) | (58,013) | 31,299 | (38,647) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (58,013) | 31,299 | (38,647) | |
| Other undisclosed net loss | ||||||||
| Net income (loss): | (13,162) | (7,810) | (20,853) | (58,013) | 31,299 | (38,647) | ||
| Other undisclosed net income (loss) attributable to parent | 213 | (31) | (59,595) | |||||
| Net loss attributable to parent: | (13,162) | (7,597) | (20,884) | (58,013) | (28,296) | (38,647) | ||
| Preferred stock dividends and other adjustments | ||||||||
| Net loss available to common stockholders, diluted: | (13,162) | (7,597) | (20,884) | (58,013) | (28,296) | (38,647) | ||
Comprehensive Income ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (13,162) | (7,810) | (20,853) | (58,013) | 31,299 | (38,647) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (13,162) | (7,810) | (20,853) | (58,013) | 31,299 | (38,647) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.